Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 7 (7), 637-42

Clinical Potential of Milnacipran, a Serotonin and Norepinephrine Reuptake Inhibitor, in Pain

Affiliations
  • PMID: 16869117
Review

Clinical Potential of Milnacipran, a Serotonin and Norepinephrine Reuptake Inhibitor, in Pain

Raphael J Leo et al. Curr Opin Investig Drugs.

Abstract

Milnacipran is a serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor currently available for use as an antidepressant in several countries. Phase III clinical trials are currently underway to assess its potential role in the treatment of fibromyalgia syndrome, and in pursuit of US Food and Drug Administration approval for this indication. Evidence has accumulated suggesting that in animal models, milnacipran may exert pain-mitigating influences involving NE- and 5-HT-related processes at supraspinal, spinal and peripheral levels of pain transmission. Preliminary evidence suggests that milnacipran may be useful in mitigating pain and fatigue associated with fibromyalgia. However, its role in addressing comorbidities associated with fibromyalgia, including visceral pain and migraine, has yet to be investigated.

Similar articles

See all similar articles

Cited by 3 articles

MeSH terms

LinkOut - more resources

Feedback